Literature DB >> 19816665

Mucosal adjuvant activity of oligomannose-coated liposomes for nasal immunization.

Mariko Ishii1, Naoya Kojima.   

Abstract

In the present study, we investigated the effectiveness of liposomes coated with a neoglycolipid consisting of mannotriose and dipalmitoylphosphatidylcholine (Man3-DPPE) as an adjuvant for induction of mucosal immunity. Immunization of BALB/c mice with ovalbumin (OVA)-encapsulated Man3-DPPE-coated liposomes (oligomannose-coated liposomes; OMLs) by a nasal route produced high levels of OVA-specific IgG and IgA antibodies in serum of immunized mice 1 week after the last nasal immunization, whereas no significant serum antibody responses were observed in mice that received OVA in uncoated liposomes or OVA alone. Seven weeks after the last nasal immunization, nasal challenge with an excess amount of OVA in mice that had received OVA/OMLs led to an anamnestic response to the antigen that resulted in 5- to 10-fold increases of antigen-specific serum IgG and IgA antibodies. Only mice immunized nasally with OML/OVA secreted antigen-specific secretory IgA in nasal washes and produced interferon-gamma secreting cells in nasopharyngeal-associated lymphoreticular tissue. Taken together, these results show that nasal administration of OMLs induces mucosal and systemic immunity that are specific for the entrapped antigen in the liposomes. Thus, liposomes coated with synthetic neoglycolipids might be useful as adjuvants for induction of mucosal immunity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19816665     DOI: 10.1007/s10719-009-9263-8

Source DB:  PubMed          Journal:  Glycoconj J        ISSN: 0282-0080            Impact factor:   2.916


  35 in total

1.  Sendai virus fusion protein mediates simultaneous induction of MHC class I/II-dependent mucosal and systemic immune responses via the nasopharyngeal-associated lymphoreticular tissue immune system.

Authors:  J Kunisawa; T Nakanishi; I Takahashi; A Okudaira; Y Tsutsumi; K Katayama; S Nakagawa; H Kiyono; T Mayumi
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

2.  Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines.

Authors:  Aviva Joseph; Igal Louria-Hayon; Alla Plis-Finarov; Evelyne Zeira; Zichria Zakay-Rones; Eyal Raz; Tomoko Hayashi; Kenji Takabayashi; Yechezkel Barenholz; Eli Kedar
Journal:  Vaccine       Date:  2002-09-10       Impact factor: 3.641

3.  Liposome oligomannose-coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes.

Authors:  M Fukasawa; Y Shimizu; K Shikata; M Nakata; R Sakakibara; N Yamamoto; M Hatanaka; T Mizuochi
Journal:  FEBS Lett       Date:  1998-12-28       Impact factor: 4.124

4.  Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant.

Authors:  H Y Wu; M W Russell
Journal:  Vaccine       Date:  1998 Jan-Feb       Impact factor: 3.641

5.  Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against hepatitis B.

Authors:  Sanyog Jain; Paramjit Singh; Vivek Mishra; S P Vyas
Journal:  Immunol Lett       Date:  2005-04-25       Impact factor: 3.685

6.  Interferon-gamma induces polymeric immunoglobulin receptor mRNA in human intestinal epithelial cells by a protein synthesis dependent mechanism.

Authors:  J F Piskurich; J A France; C M Tamer; C A Willmer; C S Kaetzel; D M Kaetzel
Journal:  Mol Immunol       Date:  1993-03       Impact factor: 4.407

7.  Preferential production of IL-12 by peritoneal macrophages activated by liposomes prepared from neoglycolipids containing oligomannose residues.

Authors:  Hideaki Takagi; Naomichi Furuya; Naoya Kojima
Journal:  Cytokine       Date:  2007-12-03       Impact factor: 3.861

8.  Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells.

Authors:  T L Stevens; A Bossie; V M Sanders; R Fernandez-Botran; R L Coffman; T R Mosmann; E S Vitetta
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

Review 9.  Myeloid C-type lectins in innate immunity.

Authors:  Matthew J Robinson; David Sancho; Emma C Slack; Salomé LeibundGut-Landmann; Caetano Reis e Sousa
Journal:  Nat Immunol       Date:  2006-12       Impact factor: 25.606

10.  Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections.

Authors:  H Jakobsen; D Schulz; M Pizza; R Rappuoli; I Jónsdóttir
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

View more
  13 in total

Review 1.  Recent progress in mucosal vaccine development: potential and limitations.

Authors:  Nils Lycke
Journal:  Nat Rev Immunol       Date:  2012-07-25       Impact factor: 53.106

2.  SIGNR1 ligation on murine peritoneal macrophages induces IL-12 production through NFkappaB activation.

Authors:  Chiaki Kato; Naoya Kojima
Journal:  Glycoconj J       Date:  2010-06-30       Impact factor: 2.916

3.  Immunotherapeutic effects of recombinant colorectal cancer antigen produced in tomato fruits.

Authors:  Se Hee Park; Kon-Young Ji; Seo Young Park; Hyun Min Kim; Sang Hoon Ma; Ju Hui Do; Hyuno Kang; Hyung Sik Kang; Doo-Byoung Oh; Jae Sung Shim; Young Hee Joung
Journal:  Sci Rep       Date:  2022-06-13       Impact factor: 4.996

4.  Liposomes and nanotechnology in drug development: focus on oncotargets.

Authors:  Tomohiro Kozako; Naomichi Arima; Makoto Yoshimitsu; Shin-Ichro Honda; Shinji Soeda
Journal:  Int J Nanomedicine       Date:  2012-09-14

5.  Targeted liposomal drug delivery to monocytes and macrophages.

Authors:  Ciara Kelly; Caroline Jefferies; Sally-Ann Cryan
Journal:  J Drug Deliv       Date:  2010-10-26

Review 6.  Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.

Authors:  Shujing Wang; Huiqin Liu; Xinyi Zhang; Feng Qian
Journal:  Protein Cell       Date:  2015-05-06       Impact factor: 14.870

7.  Strategies for intranasal delivery of vaccines.

Authors:  Mehfuz Zaman; Saranya Chandrudu; Istvan Toth
Journal:  Drug Deliv Transl Res       Date:  2012-07-12       Impact factor: 4.617

8.  The mucosal adjuvant potential of cross-linked dextran microspheres as dry powder.

Authors:  Mohsen Tafaghodi; Maryam Eskandari
Journal:  Iran J Basic Med Sci       Date:  2012-05       Impact factor: 2.699

9.  Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3.

Authors:  Kyosuke Senchi; Satoko Matsunaga; Hideki Hasegawa; Hirokazu Kimura; Akihide Ryo
Journal:  Front Microbiol       Date:  2013-11-26       Impact factor: 5.640

Review 10.  Oligomannose-coated liposome as a novel adjuvant for the induction of cellular immune responses to control disease status.

Authors:  Naoya Kojima; Mariko Ishii; Yoko Kawauchi; Hideaki Takagi
Journal:  Biomed Res Int       Date:  2013-10-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.